Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Markets & Finance

First Albany Cuts Albany Molecular Rating

First Albany downgraded its investment recommendation on Albany Molecular (AMRI) to underperform from neutral.

Analyst Kevin Berg says the downgrade was based mainly on continuing challenges facing Allegra sales. Based on his recent research, he sees a bumpy road ahead for Allegra. Berg notes that UnitedHealth is moving Allegra to the third-tier of its formulary; companies like Aetna are aggressively acting to promote OTC options; pharmacy benefit managers becoming more proactive offering clients option to allow employees to purchase OTC Claritin with a generic level co-pay. The analyst sees near-term limited growth prospects for the company. He lowered his $1.47 2003 EPS estimate to $1.44. Berg has a $21 price target on the shares.

blog comments powered by Disqus